Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. by Ryan E Feaver, M Scott Bowers, Banumathi K Cole, Steve Hoang, Mark J Lawson, Justin Taylor, Brian D LaMoreaux, Lin Zhao, Brad R Henke, Brian A Johns, Andrew C Nyborg, Brian R Wamhoff, Robert A Figler

Get full text

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis by Emma L. Shepherd, Raquel Saborano, Ellie Northall, Kae Matsuda, Hitomi Ogino, Hiroaki Yashiro, Jason Pickens, Ryan E. Feaver, Banumathi K. Cole, Stephen A. Hoang, Mark J. Lawson, Matthew Olson, Robert A. Figler, John E. Reardon, Nobuhiro Nishigaki, Brian R. Wamhoff, Ulrich L. Günther, Gideon Hirschfield, Derek M. Erion, Patricia F. Lalor

Get full text